In addition to its role in inhibiting sorafenib-induced ferroptosis in hepatocellular carcinoma cells, metallothionein 1G (MT1G) is associated with ferroptosis response and acts as a prognostic biomarker and an indicator of immune checkpoint inhibitor therapy sensitivity in patients with prostate cancer [285]. This evidence concerns the gene MT1G and Familial prostate cancer.